



Defence Research and
Development Canada

Recherche et développement
pour la défense Canada



Microarray systems for microbial detection and identification

B. N. Ford and D.E. Bader
DRDC Suffield

Defence R&D Canada

Technical Report

DRDC Suffield TR 2010-203

December 2010

Canada

Microarray systems for microbial detection and identification

B.N. Ford and D.E. Bader
DRDC Suffield

Defence R&D Canada – Suffield

Technical Report
DRDC Suffield TR 2010-203
December 2010

Principal Author
Original Signed by

Barry Ford
Defence Scientist

Approved by
Original Signed by

Stephen G. Bjarnason
Head, Casualty Management Section

Approved for release by
Original Signed by

Robin Clewley
A/Chair, Document Review Panel

This work funded by TIF Project 10DA09

- © Her Majesty the Queen in Right of Canada, as represented by the Minister of National Defence, 2010
- © Sa Majesté la Reine (en droit du Canada), telle que représentée par le ministre de la Défense nationale, 2010

Abstract

The relatively recent availability of complete or near-complete sequences of microbial DNA makes it possible to find and exploit unique genetic markers for most microbes. Using microbial genome sequences from public databases, a high-density microarray system has been developed which should enable the identification of hundreds of individual species or strains of pathogenic microorganisms on a single assay platform. This report summarizes the design, development, and testing of this microarray design. The system is currently capable of discriminating multiple human pathogens, Category A biothreats, and some agricultural pathogens, other using supervised analysis methods. Ongoing development will include tools for automation of analysis, and extension of the testing panel of microbes.

Résumé

La disponibilité relativement récente de séquences complètes ou quasi complètes d'ADN microbien nous permet de trouver et d'utiliser des marqueurs génétiques uniques pour la plupart des microorganismes. En utilisant les séquences génomiques microbiennes des bases de données, nous avons mis au point un système de biopuce à haute densité qui devrait permettre d'identifier des centaines d'espèces ou de souches de microorganismes pathogènes avec une seule et même plateforme d'essai. Nous résumons ici la conception, la mise au point et la mise à l'épreuve de cette biopuce. À l'heure actuelle, le système permet de distinguer entre de nombreux agents pathogènes pour l'humain, des bactéries de la catégorie A des agents de bioterrorisme et certains pathogènes agricoles. Le perfectionnement de la plateforme comprendra des outils pour l'automatisation des analyses et l'augmentation du nombre de microorganismes pouvant être identifiés.

This page intentionally left blank.

Executive summary

Microarray systems for microbial detection and identification:

Ford, Barry N.; Bader, Doug, B.; DRDC Suffield TR 2010-203; Defence R&D Canada – Suffield; October 2010.

Background: The relatively recent availability of complete or near-complete sequences of genomic DNA from many microorganisms makes it possible to find and exploit unique genetic markers for most microbes. These unique markers can be useful in detection and identification of microbial species, to the strain level in many cases. One tool for exploiting the availability of genetic sequence data is the DNA microarray. Microarrays are high density assay platforms which could be a useful solution to the problem of large scale screening and identification of microbial samples. Combining publicly available complete or near-complete genomic sequences from many microbial species and isolates, a microarray platform has been designed which should be able to identify many Category A biothreat, agricultural, and clinically relevant bacterial pathogens. A potential advantage of the complete microarray system is the reduced need to handle and culture live pathogens, as is required in conventional microbiology.

Results: Evaluation of the microarray with more than seventy genomic DNA isolates from a wide range of pathogenic microbes demonstrated the capability of the array to discriminate microbial species with high confidence. Within some species, strain differentiation was possible. Sample requirements and cost required the co-development of a DNA amplification technology to pre-process DNA samples, which has proven very effective.

Significance: The microarray represents a tool for identification of bioterrorism agents, water-borne or food pathogens, and selected clinical or agricultural pathogens. Current microarray technology requires skilled users and significant experience with analysis. Near-term technological developments will involve advanced automation of microarray work which will simplify the technical requirements. The microarray platform enables large-scale screening which will be useful in suspicious disease outbreaks, new pathogen detection, and monitoring spread of biological agents.

Future plans: The large data set developed during this project will require some ongoing analysis. Software to facilitate automated analysis of microarray data would represent a significant improvement. Future development of the microarray system may involve expanding the representation of agricultural and other clinical targets, including viral pathogens. Interest in exploiting the existing design has been expressed by other government departments.

Sommaire

Microarray systems for microbial detection and identification:

Ford, Barry N.; Bader, Doug, B.; DRDC Suffield TR 2010-203; R & D pour la défense Canada – Suffield; Octobre 2010.

Introduction ou contexte. La disponibilité relativement récente de séquences complètes ou quasi complètes de séquences d'ADN génomique de nombreux microorganismes nous permet de trouver et d'utiliser des marqueurs génétiques uniques pour la plupart des microorganismes. Ces marqueurs uniques peuvent servir à détecter et à identifier des espèces microbiennes, et dans de nombreux cas, ils permettent même d'identifier la souche. Un des outils d'exploitation des séquences génétiques est la biopuce à ADN. Les biopuces sont des plateformes d'essai à haute densité qui peuvent se révéler fort utiles dans le dépistage à grande échelle et l'identification de microorganismes. En utilisant les séquences génomiques complètes et quasi complètes des espèces et des isolats de microorganismes disponibles dans les banques de données publiques, nous avons conçu une biopuce qui devrait permettre d'identifier de nombreuses bactéries de la catégorie A des agents de bioterrorisme, des pathogènes agricoles et d'autres ayant une importance clinique. Un des principaux avantages du système de biopuce est qu'il permet de réduire la manipulation et la nécessité de cultiver des pathogènes vivants, comme le requièrent les méthodes classiques de microbiologie.

Résultats. L'évaluation de la biopuce avec plus de soixante-dix isolats d'ADN génomique de microorganismes pathogènes a permis de démontrer la capacité de discrimination de cet outil et sa fiabilité. Chez certaines espèces, des souches peuvent même être différenciées. Les besoins en matière de quantité d'échantillon et les coûts ont nécessité l'élaboration concomitante d'une technologie d'amplification de l'ADN pour prétraiter les échantillons, ce qui s'est révélé très efficace.

Importance. La biopuce permet d'identifier des agents de bioterrorisme, des pathogènes dans l'eau ou les aliments et certains pathogènes d'importance clinique et agricole. La technologie actuelle des biopuces requiert des utilisateurs habiles et une grande expérience dans l'analyse des résultats qu'elles génèrent. L'étape suivante du projet prévoit l'automatisation des manipulations, ce qui simplifiera l'utilisation de l'outil et les compétences techniques requises. La plateforme permet le dépistage à grande échelle qui sera utile dans le cas d'éclosions soupçonnées de maladies, de la détection de nouveaux pathogènes et de la surveillance de la prolifération ou de la dissémination d'agents biologiques.

Perspectives. De nombreuses données produites au cours de ce projet doivent encore être analysées. L'existence d'un logiciel pour faciliter l'analyse automatisée des données obtenues avec la biopuce représenterait une amélioration considérable. Le perfectionnement du système de biopuce pourrait comprendre un plus grand nombre de cibles agricoles ou cliniques, ainsi que des pathogènes viraux. Enfin, d'autres organismes gouvernementaux ont manifesté leur intérêt à utiliser la plateforme que nous mise au point.

Table of contents

Abstract	i
Résumé	i
Executive summary	iii
Sommaire	iv
Table of contents	v
List of figures	vi
List of tables	vi
Acknowledgements	vii
Introduction	1
Existing microarray systems	3
Design and Testing of the microarray	5
Testing the design	6
Results and Discussion	8
Conclusions	16
References	18
List of symbols/abbreviations/acronyms/initialisms	20
Glossary	21
Annex A .. Species and strain-specific probes in the final array design.	23
Annex B... Species and strains used in testing of the completed array design.	37

List of figures

Figure 1: Generalized microarray principle.....	2
Figure 2: DNA complementarity.....	2
Figure 3: Overall microarray system.	3
Figure 4: Genomic fingerprinting microarray workflow.....	8
Figure 5: Interpretation of Chromablast display.....	9
Figure 6: Comparison of signals from E. coli replicates.	10
Figure 7: Standard deviation versus mean signal value.	11
Figure 8: B. anthracis probe responses for various applied samples.....	12
Figure 9 : Yersinia sp. probe responses for various samples.....	13
Figure 10: C. botulinum probe responses for various samples.....	14
Figure 11 : Comparison of signals from probes for Clostridia sp.	15

List of tables

Table 1: DNA extracts used in initial testing of the microarray.....	6
--	---

Acknowledgements

The authors would like to thank Dr. Kingsley Amoako (CFIA Lethbridge) for providing bacterial DNA and sequence suggestions from various strains used in this study. Ms Cindy Ruttan from Canada West Biosciences performed most of the Affymetrix microarray processing under the management of Dr Dave Mah. Because this report is intended to summarize prior works, some figures and data in this report have been excerpted from previously published technical reports by the same authors.

The operating costs of this work were paid from a 2007 Technology Investment Fund award to Mr Doug Bader, 10DA09 - Microarray Technology For Multi-Gene Target Surveillance And Identification Of Biothreats.

This page intentionally left blank.

Introduction

Microbial genomes range widely in size and complexity. Microbiological and immunoassay technologies are widely applied in detection and identification of and Current state of the art detection and identification is primarily based on molecular assays which detect specific parts of the DNA in the genome. Ideally, for each organism of interest, one or more unique sequences are targeted which can be assayed using one of several methods. There is a wide selection of individual assay systems and methods available, a review of which is beyond the scope of this work. Invariably however, such methods require an index of suspicion as to which organism to test for, since the assay systems in general are able to identify only one or a few molecular targets in each assay run. An improvement in assay coverage wherein a single assay run could identify any of tens to hundreds of individual molecular targets would be advantageous. This report summarizes efforts to develop a solution to the multiplex-targets-for-multiple-organisms problem. The work reported was largely funded by a 2007 Technology Investment Fund award to Mr Doug Bader, 10DA09 - Microarray Technology for Multi-Gene Target Surveillance and Identification of Biothreats. It should be noted that low-specificity detection systems already exist, but high-specificity identification systems with high density target capability are lacking.

High-density DNA microarray systems offer this capability. Microarrays are essentially a tool to assay (test) a great many individual DNA targets in one interrogation. This approach has several general advantages. For example, a single microarray platform can have broad species and strain coverage potential. As well, microarrays offer the ability to do simultaneous multiple confirmatory assays within species and strains. The original program to investigate extant microarrays for the purposes of detection and identification had to be revised when microarrays specific to the project needs were either not suitable or did not become commercially available. Consequently a custom fabricated microarray was developed for this project.

The basis of microarray technology is shown in Figure 1. A sample of unknown DNA is labeled with a fluorescent dye using conventional techniques. The dye enables detection of the sample DNA using a microscope equipped with fluorescence detection capabilities. Extraction and purification of the DNA prior to labeling is required. The labeled DNA sample is mixed in a special chamber with the microarray. The microarray contains a set of “features” consisting of fragments of DNA (target DNA) attached to a solid surface, such as a microscope slide. There are multiple technologies for the preparation of the microarray itself, which are reviewed in Miller and Tang [1]. During the mixing of the sample with the microarray, fragments of the sample DNA hybridize to their complementary sequence on the microarray. The property of DNA fragments in solution coming into contact with and binding to their complementary sequence (hybridization or reassociation) is the basis of many molecular assays, including microarrays.

A key property of DNA which enables microarray and other DNA-dependent assay systems to function is the property of self-complementarity. In most organisms, the genetic material is present as double-stranded DNA. Double-stranded molecules contain two complementary copies of the DNA sequence, which in turn are comprised of linear chains of the DNA bases, adenine, cytosine, guanine, and thymine (A,C,G and T respectively). Between the single strands of the DNA, A binds to T and T to A. In the same way, C and G are complementary to each other. Overall, the two linear single chains which interact to form the double-stranded DNA molecule are complementary to each other. Each strand contains a complete "copy" of the information on the other strand. Figure 2 illustrates the principle of complementary binding of DNA fragments.




Figure 1: Generalized microarray principle.



Figure 2: DNA complementarity

In solution, after the individual linear strands are separated and fragmented, fragments reassociate to their complement by diffusion, and bind to it, reforming the double stranded DNA molecule. The rate of reassociation is related to the concentration of the fragments, and inversely related to the size of the fragments. On a microarray chip, short fragments (25 bases in this case) are present at high local concentrations in the microarray spot, such that reassociation of fragments in solution to the fragments on the array occurs relatively quickly compared to reassociation of fragments to their genomic complement. Thus the features on the microarray surface bind fragments from solution and a detectable hybridization signal is developed. Figure 3 illustrates

the system after hybridization of the sample to the microarray. The microarray with captured sample DNA is scanned by a microscope, and the digital image is stored for analysis.




Figure 3: Overall microarray system.

Existing microarray systems

At DRDC Suffield, two previous microarrays have been designed and developed on open source microscope slide formats. The results of this work have been summarized in a contractor report [2]. Using a small number of species and strains, and using open source microarrays containing either 23,000 non-specific or 5280 specific probes, this work demonstrated the proof of concept of microarrays for microbial detection and identification. The limited number of features that could be maximally placed on these arrays, combined with the intrinsic variation in the microarray spotting technology, restricted the utility of the systems to species discrimination.

Microarray systems for microbial genome analysis prior to this project have been reported. Some have used long oligonucleotide fragments which are intended to capture very specific targets. A few have attempted to use short "random" oligonucleotides, again for a relatively limited selection of targets [3–5]. A recent theoretical paper argues that it should be possible to unambiguously characterize almost all known prokaryotes and eukaryotes using approximately

two million features based on "random" oligonucleotides [6]. This approach has not been tested on an actual platform. A microarray sequencing approach has also been published for a set of food-borne pathogens, but it was not designed with sufficient scope to be able to identify Category A pathogens [7]. A microarray-based viral detection and genotyping system was developed previously at the University of California for a limited number of human viral pathogens, but is no longer available for testing [8]. This array, which used 70 base oligonucleotides on ~1600 features, was able to identify ~140 distinct viral genomes. A revision to the design eventually had 22,000 features encompassing a wide variety of rare and difficult to diagnose viral forms, and ~30 bacterial genome fragments. This chip design is now in use at Abbot Laboratories in a virus discovery program in collaboration with the University of California, and is apparently not available for distribution.

An open source chip from the Health Protection Agency (UK) has been tested for comparison to the current and previous chip designs. The HPA design contains some 9248 features nominally designed for discrimination of various pathogens¹. The chip was amenable to sample and chip processing analysis in exactly the same way as the in-house designs. Unfortunately, the HPA chip was not accompanied by adequate annotation, such that the intended targets of the chip could not be compared to the recorded data. On a qualitative basis, species could be discriminated by the HPA chip based on differential hybridization. In the absence of detailed annotation of the chip, no further analysis could be completed with this microarray.

A small number of COTS resequencing chips from TessArae (Potomac Falls, VA) were procured in the TIF project for a comparative analysis study using a small number of pathogens. The TessArae RPM-TEI Array is intended as an *in vitro* diagnostic tool to provide comprehensive detection of CDC Category A, B, and C threat agents, including differentiating closely related organisms that can be confounders [9–11]. The chip is an Affymetrix design, but uses proprietary sample and chip processing methods. The chip design is intended to perform detailed DNA sequence analysis of specific target sites in the pathogens of interest, which could offer a significant advantage in terms of detail and level of strain discrimination. The technical protocol was found to be quite complex for inexperienced users, and the first few chips were of no analytical value. Once procedural details were resolved, chip raw data were obtained, which were then transmitted to the TessArae remote server system for detailed analysis. The results were in general conformity with expectations, in that the test species could be identified by the chip system. However, in many cases the control features of the chips were reported as "failed". In the case of a diagnostic tool, control failures usually lead to failure of the assay. For the TessArae product, each chip is subject to detailed analysis by an expert user at the supplier site, thus even "failed" chips returned some useable data. While this may be an advantage in terms of reduced waste and cost, the requirement for data processing by the vendor's own computer systems using proprietary algorithms, and the common intervention of the expert users did not lend confidence to the results of the overall product.

¹ (Dr. N. Silman, personal communication)

Design and testing of the microarray

Complete details for the design and procurement of the microbial fingerprinting DNA microarray have been previously published [3,12].

A notional design for a universal genotyping microarray (or indeed, any assay system) might contain all possible DNA sequence targets of a given length which could exist. For the 25 base pair (bp) size of the oligonucleotide probes on the Affymetrix microarray, an ideal array could sample any possible sequence (known or unknown) if all possible 25-base oligonucleotides were spotted on the array. It would require 1.126×10^{15} individual features (A, C, G or T at all 25 positions (4^{25}) or $\sim 1.126 \times 10^{15}$ individual sequences). This would in turn require 1×10^9 microarrays (assuming a maximum of 1×10^6 features per array) to cover most of the possible sequences. Thus, designing an array with all possible 25 base pair sequences was not a feasible approach. It was necessary therefore to develop a discrete set of species and strain-specific target sequences, which was accomplished using publicly available database sources, and the services of Affymetrix in the final design and fabrication of the arrays.

The first step in identifying regions of interest was to review the existing literature on bacterial microarray genotyping and strain differentiation. This provided a partial list of genes to include in our search. Next, various online databases were investigated for genes of interest. Initially, the NCBI Protein Clusters database [13] was used. Antibiotic resistance gene names and accessions were obtained from the Antibiotic Resistance Genes Database [14]. The majority of the resistance gene sequences used for probe selection was obtained from VFDB, the Virulence Factors of Pathogenic Bacteria database [15].

Organisms included in the search were derived from the National Institute of Allergy and Infectious Diseases Category A and B list of priority pathogens [16]. Also selected were *Haemophilus influenzae*, *Acinetobacter baumannii*, *Chaetomium* species, *Rickettsia* species, and plasmids pBC16 and pLS1 (containing tetracycline resistance genes). Sequences representing bacterial toxins and antimicrobial resistance sequences (*e.g.* other antibiotic markers) were also sampled. Targets for viral pathogens were not included in this chip. Redundancy is built into the Affymetrix microarray technology, wherein variants of specific probe sequences differing by one or a few bases from the specific probe are used to assess non-specific or variant binding to probe sites. The number of microbial genomic targets thus does not equal the number of individual probes on the array. In general, each specific target is represented by 3–20 individual probe sequences, varying by length, sequence, or single base pair differences. In typical applications, only one summary signal is reported from a probe set, the remaining features serving as quality assurance and quality control indicators. For genomic fingerprinting, however, variants related to (but not identical to) the primary probe may also contain useful signals and are also reported.

The design targeted approximately 16,000 individual sequence targets, which, allowing for sequence variants and internal controls, led to over 81,000 unique probes. The remaining capacity of the chip surface contained $\sim 140,000$ probes from the Affymetrix "antigenomic library" to serve as non-targeted probes, essentially a random target library.

The final microarray design was assembled using 81,678 probes from 11,516 unique microbial sequences, 24,660 probes from 264 SNP sequences, and approximately 140,000 non-specific probes along with controls to fill in the 220,678-probe chip. Annex A contains the listing of species- and strain-specific probes on the final microarray design. The Affymetrix proprietary technology for microarray preparation is also described in reference 12. One aspect of the Affymetrix approach is the control of the intellectual property around the chip design. Interested

users of this design must obtain the permission of the owner/designer to order the chip from Affymetrix, until the design is released into the public domain, or licensed for commercial use.

In silico verification of the design of the sequences on the chip versus available genome data was performed by iterative searches of the NCBI genome databases. Since the entire feature sequence set was designed using publicly available databases, of which NCBI comprises a large, if not exhaustive aggregation, it was anticipated, and found, that *in silico* testing would recapitulate the expected species and strain identifications.

Testing the design

Table 1 lists the microbial DNA samples used for preliminary testing of the custom microarray design. DNA samples from *E. coli* were prepared by Canada West Biosciences, while DNA from level 2 and level 3 microbes was prepared by DRDC Suffield in DRDC. These latter DNA extracts were tested for sterility using standard procedures within the respective containment facilities prior to release for microarray testing. Additional DNA samples were obtained from the Canadian Food Inspection Agency and commercial sources. Due to cost and poor availability of some of the DNA samples, an isothermal genomic amplification method was developed, exploited, and adopted for routine use to enhance the quantity of genetic material for testing purposes [17]. The amplification protocol is now part of the routine method for this microarray, enabling the future testing of other sparse or rare samples. Protocols for processing the DNA samples and the microarrays have been previously described [12].

Table 1: DNA extracts used in initial testing of the microarray.

Genus	Species	Strain / Isolate
Escherichia	coli	JM109
Bacillus	anthracis	94188c (RP42)
Bacillus	cereus	ATCC 11778
Yersinia	pestis	ATCC 19428
Yersinia	enterocolitica	YE-D3

After preliminary testing, an extensive (although not exhaustive) collection of DNA samples representing different species and strains were also tested on the microarray. Annex A lists all the possible species and strains which could have been tested. Annex B contains a listing of all species and strains which were tested more than once during this project.

Digitized chip scanner images were collated on Excel spreadsheets (Microsoft, Seattle, WA). Notably, Office 2007 is the first commercial spreadsheet program capable (without modification) of capturing the entirety of the digital data from a single microarray, let alone from the entire set in excess of 100 arrays.

As there were no pre-existing software tools for analysis of the microarrays in this project, various other software tools used for gene expression arrays were exploited to analyze the data.

Due to the large size of the data sets (244,000 rows, >100 columns), no extant microarray software was useful for comparisons between sample data sets. To circumvent this difficulty, manual data reduction procedures were performed. For pair wise comparison (i.e. species vs species), average intensity values in excess of a minimum cut-off value (0.5% of 65535, or 325) were used. To verify difference (or not) between samples, two-tailed Student's t-tests were used. For visualization of large scale data summaries, Chromablast [18] or MS Excel built-in conditional formatting tools were used.

Results and Discussion

Data were obtained during preliminary testing on the Affymetrix custom-designed microarray for DNA samples from *Escherichia coli*, *Yersinia pestis*, *Yersinia enterocolitica* and *Bacillus anthracis*. Few analytical tools are available for comparing and discriminating results in genomic fingerprint data, thus for this testing phase qualitative comparison was used. A summary of the microarray workflow is shown in Figure 4.




Figure 4: Genomic fingerprinting microarray workflow.

Using Chromablast [18], a heat map representing relative signal values was developed for a series of technical replicates of *E. coli* and used for the microarray testing. Figure 5 represents an interpretive key to understanding the data display generated by Chromablast. The full display for a complete data set covers multiple pages. An excerpt of a Chromablast analysis showing a region of the *E. coli* replicate data is shown in Figure 6. Uniform heat map colour across the replicates

would indicate perfect concordance on each target between replicates. The excerpt region shows examples of this, as well as some targets with varying colour, indicating some variation across the replicates. In Figure 6, green represents low value intensities (i.e. background to about 12% of maximum intensity, 0 to 6 in log base 2), and bright red indicates maximal intensity, as indicated in the scale below the heat map. This colour choice is a conventional display in the microarray literature; Chromablast offers a choice of 256 colours in any order. The absolute scale of variation between non-normalized array data sets is seen to be about 30% within individual probe sets. This is verified by numerical analysis of the raw intensity data. Most of this variation is concentrated within the lower intensity values, where the standard deviation as a fraction of the mean is maximal. Above the mean signal intensity (~ 7.0 in log 2), the maximum signal variation per probe set is about 5% (scatter plot in Figure 7). In practice this means that higher signal values have lower variation, and represents data in which the highest confidence may be placed.




Figure 5: Interpretation of Chromablast display.

In practice, this suggests that a pruning of low-intensity signals may be useful to refine discrimination between samples versus knowns. One method to compensate for signal variation between replicate arrays is to use Student's t-test to compare knowns to unknowns. In the case of the *E. coli* replicated data set, for the complete data set, including the lowest value probe intensities (15,533 probe sets), less than 2% of all signals in a pair wise comparison have a t-test value of less than 0.05. If only the signals greater than the minimum cutoff value (0.5% of 65535, or 325) are considered, the number of t-test values less than 0.05 falls to ~1% (72 probe sets). "Significant" t-test results obtained for low-intensity signals (low confidence) are thus removed.




Figure 6: Comparison of signals from *E. coli* replicates.




Figure 7: Standard deviation versus mean signal value.

If one selects as an upper limit a standard deviation of $\pm 10\%$, this corresponds to about 2^8 in this data set. In practice this limit falls in the range of 2^8 to 2^9 (intensity range of 256–512). Thus the value of intensity used in the preliminary analysis (325 or 0.5% of maximal intensity) has been shown to be quite reasonable. Such a discriminator still leaves several thousand features for comparison between samples, most of which have relatively small variation. Occurrences of outliers or systematically unreliable signal sets, as indicated by this analysis, are unlikely to interfere with discrimination between different genera or species, but may complicate detailed discrimination between closely related strains.

In Figure 8, a display of 210 signals from probes designed to detect *Bacillus anthracis* is shown. In this case, data from eight microarrays are shown. Each sample was independently hybridized to separate arrays in duplicate. The samples from left to right are *E.coli* JM109, *Yersinia enterocolitica* YE-D3, *Yersinia pestis* ATCC 19428, and *Bacillus anthracis* RP42. Notably the *B. anthracis* DNA sample yields a high frequency of high-intensity signals, shown as red bars. A few of the designed probes exhibit low intensity values (green bars), usually close to background values.




Figure 8: *B. anthracis* probe responses for various applied samples.

The observation that not all probes designed for a given species would yield positive signals was repeated for all of the DNA samples tested. Given that the probe design is derived from publicly available sequence resources, it is likely that some strain-specific (or sequence record specific) differences exist between the design and the test DNA. Note that some clear positive signals for *B. anthracis* probes occur in samples of *E.coli* DNA. This represents a strong case for multiple redundant probes for the microbes of interest, such that multiple points of identity and difference can be found for any species or strain tested.

Figure 9 is a display of data from the same set of microarrays as in Figure 8. In this case, the data have been filtered and excerpted to review the response of probes designed to detect *Y. enterocolitica* versus *Y. pestis*. These two species have very little overlap at the highest scoring microarray probes. One probe in the lower half of the figure, indicated by an arrow, shows just above background signal for *Y.pestis* (although it was designed to detect *Y.pestis*), and also similar signal intensity for *Y. enterocolitica*. This probe has a low signal in *E.coli* samples as well, but none in *B.anthraxis*. This is an indication that the pattern of signals (as opposed to presence

versus absence) is also likely to be useful in species or strain discrimination, although patterns are much more difficult to analyze.




Figure 9 : *Yersinia* sp. probe responses for various samples.

The microarray design is capable of detecting by absence as well as presence of signals. For example, in Figure 10, the probes designed to detect *Clostridium botulinum*, for the most part do not yield request signals from *E. coli*, *Yersinia* sp., or *Bacillus anthracis*. Unfortunately, DNA samples from *C. botulinum* were not available during this study. A sample of *Clostridium perfringens* was used to test the response of the microarray to *Clostridia* sp. Of 2682 probes designed to detect *Clostridia* of various species, 297 should detect *C. perfringens* with some specificity. In panel A of Figure 11, the samples of *C. perfringens* (Cpe) are detected by 154 of the 297 probes, at signals above the cutoff limit of 325. For comparison, *C. jejuni* (Cje) DNA yields no positive signals on probes for *C. perfringens*.




Figure 10: *C. botulinum* probe responses for various samples.

Conversely, in panel B of Figure 11, an excerpt of 297 probes designed to detect *Clostridium botulinum* are shown, with corresponding signals generated by DNA from *C. perfringens* and *C. jejuni*. An additional 300 *C. botulinum* probes not shown here have an equally uniform pattern of signals at or near background. There is essentially no crosstalk between the conspecific probes for these two species. This figure demonstrates visually the requirement to have multiple probes for any given species to be interrogated, and the usefulness of negative as well as positive signals. If some of the probes designed to yield positive signals fail, the multiplicity of targets still yields sufficient data for confident identification. Negative signals reinforce the interpretation that one is not simply observing a related strain.




Figure 11 : Comparison of signals from probes for *Clostridia* sp.

Conclusions

Using a microarray platform, it is possible to assay thousands of targets at once, in every sample. A microarray in this application is a microscope slide or silicon chip onto which are spotted thousands of DNA probe sequences, each of which can detect one or more unique fragments of DNA. Using DNA probes which are designed to be specific to known microbial sequences, one can identify the species and strain of organism under examination.

The very specificity of the DNA hybridization phenomenon, however, would seem to preclude the ready detection of the presence of novel genetic sequences which might occur in unknown or recombinant organisms. In the absence of prior knowledge of the precise DNA sequence of the organism, it is not possible to build specific microarray targets to detect that DNA. In order to relieve the requirement for prior knowledge of all possible genetic content, the application of non-specific probes may be useful. For example, by selecting DNA sequences which do not explicitly correspond to known microbial sequences, one can detect the presence of novel or unexpected genetic sequences in the microbe. A sufficient panel of non-specific sequences in itself provides a unique “fingerprint” for any microbe, since each strain will exhibit a different “fingerprint” which can be measured. In addition, by using DNA probes specific for known “threat factors” (for example antibiotic resistance, virulence, etc.) that are not pathogen-specific, one can add the ability to identify organisms that have been genetically modified to include these traits. An organism carrying unusual or unexpected resistance or virulence genes represents an increased threat. Probes specific to known cloning vector fragments have the added virtue of detecting recombinants which are likely to be of laboratory origin rather than naturally occurring.

The combination of the “random” sequence fingerprint added to the panels of known sequences (microbial genes, antibiotic resistance, etc.) can offer a tool for identification of species or strain, and the presence of foreign genetic material. The reproducibility of such patterns on a given microarray design demonstrates that the hybridization of the genomic DNA to the features is sequence specific and not random. A further consideration is that the hybridizations are probably not context specific. That is, if a genome has been rearranged, it will in general contain the same sequence content, in altered context. Other genomic fingerprinting techniques such as restriction fragment length polymorphism (RFLP), amplified fragment length polymorphism (AFLP), or similar pulsed field techniques require positional stability to correctly indicate that the organism is genetically different from library samples, even if functionally (i.e. microbiologically) similar. Using hybridization techniques that do not require stable overall genome structures (e.g. PCR or microarrays) means that we should be able to identify and compare genomic content without much interference from contextual alterations. This hypothesis has not yet been tested, and it is not known at this point what the sampling density of the genomic DNA is or whether it is sensitive to positional changes within the genome.

The importance of the problem of recombinants has been demonstrated in a published account of a modified mouse pox virus (related to human smallpox) containing an extra gene encoding mouse interleukin-4 [19]. When exposed to the modified virus, mice vaccinated against mouse pox and mice that are genetically resistant to the normal virus exhibit mouse pox symptoms and high mortality. Methods by which such modifications to potential biowarfare agents can be made have also been published, emphasizing the need to understand the possibility of novel pathogens created by intention, and for tools to detect such recombinants [20,21].

The application of microarrays to microbial genotyping or fingerprinting is a technical compromise of time and difficulty versus data density. Single target or multiplex real-time PCR assays are faster and can be quantitative. Real-time PCR assays can in principle detect down to 1-10 targets per assay reaction, based on positive detection of specific sequences in known genomic targets. Routine PCR assays are not the best method of choice for detecting recombinants, variants, or the presence of non-target organisms however. If an assay system could run hundreds of PCR reactions for each test sample, the analytical density of the microarray could be equalled. Typical microarray open source platforms can detect 20–50,000 targets per array, using a single labelling or amplification reaction. Open source microarray systems typically take 18–26 hours for a single execution, but each run encompasses the equivalent of one to two thousand multiplex PCR reactions.

The number of assays executed per microarray has the drawback, that for some samples, DNA from multiple species is likely to be present and may contribute to the measured signals [22]. If the microarray contains sufficient numbers of features and has a high degree of automation, endemic species are always going to give a signal; thus, the mere presence of a signal of such a species in a given environmental or clinical context is not in itself meaningful. Assays must be combined with other indices of suspicion (clinical signs, known exposure, suspect samples) in order to determine whether a given positive represents a real diagnosis or threat [23]. This is also true for most other molecular or microbiological assays currently in use. Simple detection of DNA from pathogens is insufficient to establish a diagnosis in a clinical setting. For example, healthy individuals may carry pathogenic bacteria as part of their flora, but not suffer concurrent disease symptoms from that microbe. Clinical detection of a pathogen will be combined with other signs and symptoms to confirm the diagnosis.

In addition, as the sensitivity of assay systems improves (due to non-specific genomic amplification for example), out-of-context true positive signals (not within the normal range of endemics) may be detected. Such signals may be due to sample contamination by workers, gratuitous sampling of infrequent (but locally intense) organism populations, or previously undetected genetic similarity between lab strains and endemic strains. Use of confirmatory assays of high-specificity (e.g. real-time PCR) will complement such data.

Given the requirement for technical expertise in operating a microarray system, and given the sensitivity to multiple targets in some samples, microarray systems will continue to require sophisticated laboratory support. Microarray systems are in use in clinical centers, but point-of-care microarray systems are not imminent. On the other hand, time-to-result times are comparable to or better than conventional microbiology. Detailed testing of the current microarray and comparison to other microarray systems is underway. Additional testing with an expanded library of DNA samples and a wider sampling of species is required to fully assess the value of the microarray as a tool for diagnosis, detection, and identification of microbial samples. Because of the capacity and specificity of microarrays, coupled with the technical challenges and level of expertise required for use, microarrays should be considered as a useful complement to existing PCR, RFLP, or AFLP technologies.

References

- Miller, M. and Tang, T. (2009), Basic concepts of microarrays and potential applications in clinical microbiology. *Clin Microbiol Rev.* 22:611-633.
- Lam, V., Crichton, M., Laing, T. and Mah, D. (2008), Microarray genomic systems development (DRDC Suffield CR2008-154), Canada West Biosciences, Camrose, Alberta.
- Kostrzynska, M. and Bachand, A. (2006), Application of DNA microarray technology for detection, identification, and characterization of food-borne pathogens. *Can. J. Microbiol.* 52:1-8.
- Willse, A., Straub, T., Wunschel, S., Small, J., Call, D., Daly, D. and Chandler DP. (2004), Quantitative oligonucleotide microarray fingerprinting of *Salmonella enterica* isolates. *Nucleic Acids Res.* 32:1848-1856.
- Kingsley, M., Straub, T., Call, D., Daly, D., Wunschel, S. and Chandler, D. (2002), Fingerprinting closely related *Xanthomonas* pathovars with random nonamer oligonucleotide microarrays. *Appl. Environ. Microbiol.* 68: 6361–6370.
- Liu, Z., Venkatesh, S. and Maley, C. (2008), BMC Sequence space coverage, entropy of genomes and the potential to detect non-human DNA in human samples. *BMC Genomics* 9:509.
- Ayodeji, M., Kulka, M., Jackson, S., Patel, I., Mammel, M., Cebula, T. and Goswami, B. (2009), A microarray based approach for the identification of common foodborne viruses. *The Open Virology Journal* 3:7-20.
- Wang, D., Coscoy, L., Zylberberg, M., Avila, P., Boushey, H., Ganem, D. and DeRisi, J. (2002), Microarray-based detection and genotyping of viral pathogens. *P.N.A.S.* 99:15687-15692.
- Malanoski, A., Lin, B., Wang, Z., Schnur, J. and Stenger, D. (2006), Automated identification of multiple micro-organisms from resequencing DNA microarrays. *Nucleic Acids Res.* 34:5300-5311.
- Leski, T., Malanoski, A., Stenger, D. and Lin, B. (2010), Target amplification for broad spectrum microbial diagnostics and detection. *Future Microbiol.* 5:191-203.
- Leski, T., Baochuan, L., Malanoski, A., Wang, Z., Long, N., Meador, C., Barrows, B., Ibrahim, S., Hardick, J., Atichou, M., Schnur, J., Tibbets, C. and Stenger, D. (2009), Testing and validation of high density resequencing microarray for broad range biothreat agents detection. *PLoS ONE* 4: e6569.
- Ford, B., Bader, D., Shei, Y., Ruttan, C. and Mah, D. (2009), An Affymetrix microarray design for microbial genotyping (U), (DRDC Suffield TM 2009-183) Defence R&D Canada – Suffield.
- Protein Clusters (ProtClustDB). (2010), National Center for Biotechnology Information. <http://www.ncbi.nlm.nih.gov/proteinclusters> (Access date 25 Jan. 2008).
- Liu, B. and Pop, M. (2008), ARDB_Antibiotic resistance genes database. *Nucleic Acids Res.* 37:D443-D447. <http://ardb.cbcb.umd.edu> (Access date 24 Jan. 2008).
- Chen, L., Yang, J., Yu, J., Yao, Z., Sun, L., Shen, Y. and Jin, Q. (2005), VFDB: a reference database for bacterial virulence factors. *Nucleic Acids Res.* 33:D325-D328. <http://www.mgc.ac.cn/VFs/main.htm> (Access date 2 Feb. 2008).

NIAID Category A, B, and C Priority Pathogens. National Institute of Allergy and Infectious Diseases. (2008), <http://www.niaid.nih.gov/topics/biodefensereLATED/biodefense/research/pages/cata.aspx> (Access date: 2 Feb. 2008).

Ford, B., Bader, D., Ruttan, C., and Mah, D. (2010), Isothermal amplification of microbial genomic samples (DRDC Suffield TM2010-143 (in press)) Defence R&D Canada–Suffield.

Ford, B., Shei, Bjarnason, S. and Richardson, C. (2006), ChromaBlast- a data visualization tool (DRDC Suffield TM2006-049), Defence R&D Canada – Suffield.

Jackson, R., Ramsay, A., Christensen, C., Beaton, S., Hall, D. and Ramshaw, I. (2001), Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. *J. Virol.* 75:1205-1210.

Galams, F. (2008), Biological weapons, nuclear weapons, and deterrence; the biotechnology revolution. *Comparative Strategy* 27:315-323.

Buller, M. (2004), Mousepox; a small animal model for biodefense research. *Applied Biosafety* 9:10-19.

Venter, J., Remington, K., Heidelberg, J., Halpern, A., Rush, D., Eisen, J., Wu, D., Paulsen, I., Nelson, K., Nelson, W., Fouts, D., Levy, S., Knap, A., Lomas, M., Nealson, K., White, O., Peterson, J., Hoffman, J., Parsons, R., Baden-Tillson, H., Pfannoch, C., Roger, Y., Smith, H. (2004), Environmental genome shotgun sequencing of the Sargasso sea. *Science* 304:66-74.

Tomioka, K., Peredelchuk, M., Zhu, X., Arena, R., Volokhov, D., Selvapandiyan, A., Stabler, K., Mellquist-Riemenschneider, J., Chizhikov, V., Kaplan, G., Nakhasi, H. and Duncan, R. (2005), A multiplex polymerase chain reaction microarray assay to detect bioterror pathogens in blood. *J. Mol. Diag.* 7:486-494.

List of symbols/abbreviations/acronyms/initialisms

AFLP	amplified fragment length polymorphism
APRT	adenine phosphoribosyltransferase
ATCC	American Type Culture Collection; an organization supplying standard microbial strains and samples
BLAST	Basic Local Alignment Search Tool
bp	base pair
BSL2	Biosafety Containment Level 2
BSL3	Biosafety Containment Level 3
dNTP	dATP, dCTP, dGTP, dTTP : deoxynucleotide triphosphates of DNA bases
DNA	Deoxyribonucleic acid
DRDC	Defence Research & Development Canada
HPT	hypoxanthine guanine phosphoribosyltransferase (also HPRT)
mM	millimolar
NCBI	National Center for Biotechnology Information (also referred to as Genbank)
PCR	Polymerase chain reaction
R&D	Research & Development
RFLP	Restriction fragment length polymorphism
RNA	Ribonucleic acid
SNP	single nucleotide polymorphism; a sequence variant at one base position which may be different between populations or individuals
TDT	terminal deoxynucleotidyl transferase
TIFF	Tagged Image File Format
TRIS	2-amino-2-hydroxymethyl-1,3-propanediol

Glossary

<i>feature</i>	a location on a microarray surface which has a known (or mappable) two dimensional location (X and Y coordinates), and contains DNA fragments or oligonucleotides which may serve as a capture probe for a complementary fragment in the sample mixture.
<i>fingerprint</i>	a collection of signal intensity scores, digitized from an image of a hybridization of genomic DNA to a microarray spotted with DNA fragments. The fingerprint of a given species and strain is unique from that of other species or strains.
<i>gene</i>	a DNA sequence which encodes a single inheritable genetic trait
<i>genus</i>	a taxonomic grouping of species by (among others) morphology, ecology, or origin
<i>genomic DNA</i>	the DNA which comprises the genetic material of an cell, and is inherited by the progeny of the cell. The sequence of nucleotides in the genomic DNA comprises the genes, and determines the properties of the microbe. For many microbes, the genomic DNA sequence is in the public domain.
<i>hybridization</i>	sample DNA (or RNA) is tagged with a fluorescent dye, then applied to the surface of the microarray. Under controlled conditions, sequences in the sample DNA which correspond to sequences in the microarray features, will bind to the features (hybridize). Hybridization often refers to the entire process from labeling to binding, to post incubation washing.
<i>microarray</i>	a microscope slide, filter membrane or other solid surface, onto which DNA fragments have been spotted (features) in an organized grid.
<i>nucleotide</i>	the components of DNA are the nucleotides deoxyadenosine monophosphate, deoxycytidine monophosphate, deoxyguanosine monophosphate, deoxythymidine monophosphate, and the chemical bonds which join them into long chains. Genetic information is encoded in the order in which the nucleotides occur in the DNA chain.
<i>oligonucleotide (oligo)</i>	a fragment of DNA (or RNA) representing a section of genetic material from which the sequence may be known. Oligos may also be “random” in sequence, such that the sequence is not derived from known sequences
<i>species</i>	the grouping of microbes according to significant genetic differences (e.g. the ability to grow (or not) in an oxygen-free environment)
<i>strain</i>	a microbe which differs from other members of the same species by minor or additional genetic characters (e.g. resistance or sensitivity to penicillin).

This page intentionally left blank.

Annex A Species and strain-specific probes in the final array design.

Organism	Strain / details	Probes on Array
<i>Acinetobacter baumannii</i>	ACICU	38
<i>Acinetobacter baumannii</i>	ATCC 17978	54
<i>Acinetobacter baumannii</i>	AYE	143
<i>Acinetobacter baumannii</i> SNP	baumannii	20
<i>Acinetobacter baumannii</i>	baumannii	15
<i>Acinetobacter baumannii</i>	plasmid pSUN-5	5
<i>Acinetobacter baumannii</i>	SDF	44
<i>Acinetobacter baumannii</i> HPT	ATCC 17978	5
<i>Acinetobacter baumannii</i> HPT	AYE	5
<i>Acinetobacter baumannii</i> HPT	baumannii	5
<i>Bacillus anthracis</i>	Ames ancestor	140
<i>Bacillus anthracis</i>	Ames ancestor plasmid pX01	5
<i>Bacillus anthracis</i>	Ames ancestor plasmid pX02	25
<i>Bacillus anthracis</i>	anthracis	45
<i>Bacillus anthracis</i>	Australia 94	6
<i>Bacillus anthracis</i>	Kruger	5
<i>Bacillus anthracis</i>	Sterne	55
<i>Bacillus anthracis</i> APRT	A2012 plasmid pXO1	5
<i>Bacillus anthracis</i> APRT	Ames	5
<i>Bacillus anthracis</i> HPT	A0442	5
<i>Bacillus anthracis</i> HPT	anthracis	5
<i>Bacillus anthracis</i> HPT	anthracis	10
<i>Bacillus anthracis</i> plasmid	Sterne plasmid pX01+pX02-	10
<i>Bacillus anthracis</i> SNP	A2012	20
<i>Bacillus anthracis</i> SNP	anthracis	780
<i>Bacillus anthracis</i> SNP	other anthracis	200
<i>Bacillus anthracis</i> SNP	W. North America	20
<i>Bacillus cereus</i>	ATCC 10987	179
<i>Bacillus cereus</i>	ATCC 14579	200
<i>Bacillus cereus</i>	B. cereus plasmid pBCX01	5
<i>Bacillus cereus</i>	E33L	45
<i>Bacillus cereus</i>	G9241	5
<i>Bacillus cereus</i> group SNP	Bacillus	1800
<i>Bacillus cereus</i> HPT	E33L	5
<i>Bacillus cereus</i> SNP	ATCC 10987	80
<i>Bacillus cereus</i> SNP	ATCC 14579	320
<i>Bacillus cereus</i> SNP	B. cereus plasmid pBCX01	320
<i>Bacillus cereus/anthracis</i> SNP	B. cereus plasmid pBCX01	20
<i>Bacillus amyloliquefaciens</i> APRT	FZB42	5
<i>Bacillus clausii</i>	KSM-K16	5
<i>Bacillus clausii</i> APRT	KSM-K16	5
<i>Bacillus halodurans</i>	C-125	5

<i>Bacillus halodurans</i> APRT	C-125	5
<i>Bacillus licheniformis</i>	ATCC 14580	35
<i>Bacillus licheniformis</i> APRT	ATCC 14580	5
<i>Bacillus pumilus</i> APRT	SAFR-032	5
<i>Bacillus subtilis</i>	168	25
<i>Bacillus subtilis</i> APRT	168	5
<i>Bacillus thuringiensis</i>	97-27	115
<i>Bacillus thuringiensis</i>	Al Hakam	130
<i>Bartonella bacilliformis</i>	ATCC 35685	175
<i>Bartonella henselae</i>	Houston-1	270
<i>Bartonella quintana</i>	Toulouse	245
<i>Bartonella tribocorum</i>	CIP 105476	330
<i>Bordetella</i> SNP	Bordetella	20
<i>Bordetella avium</i>	197N	440
<i>Bordetella avium</i> APRT	197N	5
<i>Bordetella bronchiseptica</i> APRT	RB50	5
<i>Bordetella bronchiseptica</i>	RB50	75
<i>Bordetella parapertussis</i>	12822	268
<i>Bordetella pertussis</i> APRT	Tohama I	5
<i>Bordetella pertussis</i>	Bordetella	5
<i>Bordetella pertussis</i>	Tohama I	615
<i>Bordetella petrii</i> APRT	DSM 12804	5
<i>Borrelia afzelii</i> APRT	PKo	5
<i>Brucella</i> SNP	9-941	20
<i>Brucella</i>	all brucella	250
<i>Brucella</i> HPT	all brucella	5
<i>Brucella abortus</i>	9-941	30
<i>Brucella abortus</i>	S19	45
<i>Brucella abortus</i> SNP	melitensis/abortus	40
<i>Brucella abortus</i> APRT	9-941	5
<i>Brucella abortus/melitensis</i> SNP	abortus/melitensis	20
<i>Brucella abortus/suis</i> SNP	abortus/suis	20
<i>Brucella canis</i>	ATCC 23365	15
<i>Brucella canis</i>	S19	5
<i>Brucella canis</i> HPT	ATCC 23365	10
<i>Brucella melitensis</i>	16M	427
<i>Brucella melitensis</i>	2308 bv Abortus	210
<i>Brucella melitensis</i>	bv Melitensis	10
<i>Brucella melitensis</i>	bv Suis 686	5
<i>Brucella ovis</i>	ATCC 25840	82
<i>Brucella ovis</i>	bv Abortus 2308	35
<i>Brucella suis</i>	1330	25
<i>Brucella suis</i>	ATCC 23445	5
<i>Brucella suis</i>	ATCC 23447	5
<i>Brucella suis</i>	ATCC 25840	10
<i>Brucella suis</i>	bv. 4 str. 40	15
<i>Brucella suis/abortus</i> SNP	suis/abortus	80
<i>Burkholderia</i> SNP	Burkholderia	1160
<i>Burkholderia</i> HPT	all burkholderia	5
<i>Burkholderia mallei</i> APRT	ATCC 23344	5

<i>Burkholderia mallei</i>	ATCC 23344	40
<i>Burkholderia mallei</i>	PRL-20	5
<i>Burkholderia multivorans</i> APRT	ATCC 17616	5
<i>Burkholderia pseudo/mallei</i> SNP	pseudomallei/mallei	20
<i>Burkholderia pseudo/mallei</i>	Burkholderia	15
<i>Burkholderia pseudomallei</i>	668	10
<i>Burkholderia pseudomallei</i>	1710b	5
<i>Burkholderia pseudomallei</i>	392f	5
<i>Burkholderia pseudomallei</i> SNP	B7210	40
<i>Burkholderia pseudomallei</i>	K96243	75
<i>Burkholderia pseudomallei</i> SNP	pseudomallei	340
<i>Burkholderia pseudomallei</i>	pseudomallei	5
<i>Burkholderia pseudomallei</i>	T18-1984	5
<i>Burkholderia pseudomallei</i> HPT	91	5
<i>Burkholderia pseudomallei</i> HPT	668	5
<i>Burkholderia pseudomallei</i> HPT	NCTC 13177	5
<i>Burkholderia pseudomallei</i> APRT	668	5
<i>Burkholderia thailandensis</i> APRT	E264	5
<i>Campylobacter concisus</i> APRT	13826	5
<i>Campylobacter fetus</i>	82-40	440
<i>Campylobacter hominis</i> APRT	ATCC BAA-381	5
<i>Campylobacter jejuni</i> APRT	doylei 269.97	5
<i>Campylobacter jejuni</i>	269.97 ss doylei	476
<i>Campylobacter jejuni</i>	81116 (NCTC 11828)	351
<i>Campylobacter jejuni</i>	81-176	349
<i>Campylobacter jejuni</i>	jejuni	60
<i>Campylobacter jejuni</i>	NCTC 11168	560
<i>Campylobacter jejuni</i>	plasmid pCjA13 t	5
<i>Campylobacter jejuni</i>	RM 1221	304
<i>Campylobacter jejuni</i> APRT	81-176	5
<i>Campylobacter jejuni</i> plasmid	81-176 plasmid pVir	5
<i>Chaetomium atrobrunneum</i>	atrobrunneum	5
<i>Chaetomium funicola</i>	funicola	29
<i>Chaetomium funicola</i>	OC13	5
<i>Chaetomium funicola</i>	olrim130	5
<i>Chaetomium thermophilum</i>	CT2	20
<i>Chaetomium thermophilum</i>	MTCC 6350	5
<i>Chaetomium thermophilum</i>	thermophilum	85
<i>Chlamydia abortus</i>	S26/3	115
<i>Chlamydia caviae</i>	GPIC	115
<i>Chlamydia felis</i>	Fe/C-56	120
<i>Chlamydia muridarum</i>	Nigg (MoPn)	115
<i>Chlamydia pneumoniae</i>	AR39	115
<i>Chlamydia pneumoniae</i>	CWL 029	5
<i>Chlamydia trachomatis</i>	D/UW-3/CX	175
<i>Chlamydia trachomatis</i>	HAR-13	15
<i>Chlamydia trachomatis</i>	trachomatis	5
<i>Clostridium botulinum</i> APRT	Alaska E43	10
<i>Clostridium botulinum</i> APRT	ATCC 3502	5
<i>Clostridium botulinum</i> APRT	Eklund 17B	5

<i>Clostridium botulinum</i> APRT	Okra	5
<i>Clostridium botulinum</i>	A str. ATCC 19397	5
<i>Clostridium botulinum</i>	ATCC 3502	40
<i>Clostridium botulinum</i>	B str. Eklund 17B	5
<i>Clostridium botulinum</i> SNP	B1 str. Okra plasmid pCLD	20
<i>Clostridium botulinum</i>	B1 str. Okra plasmid pCLD	5
<i>Clostridium botulinum</i>	Bf	5
<i>Clostridium botulinum</i> SNP	botulinum	1860
<i>Clostridium botulinum</i>	C str. Eklund	5
<i>Clostridium botulinum</i> SNP	C. botulinum A strains	100
<i>Clostridium botulinum</i>	C. botulinum A strains	5
<i>Clostridium botulinum</i>	<i>Clostridium botulinum</i>	15
<i>Clostridium botulinum</i>	Hall 183	5
<i>Clostridium botulinum</i> HPT	Alaska E43	15
<i>Clostridium botulinum</i> HPT	Eklund 17B	10
<i>Clostridium botulinum</i> HPT	Loch Maree	20
<i>Clostridium botulinum</i> HPT	Okra	5
<i>Clostridium botulinum</i>	A3 str. Loch Maree	5
<i>Clostridium acetobutylicum</i>	ATCC 824	25
<i>Clostridium beijerinckii</i>	NCIMB 8052	20
<i>Clostridium difficile</i>	630	45
<i>Clostridium difficile</i>		15
<i>Clostridium difficile</i> HPT	difficile	5
<i>Clostridium kluyveri</i> APRT	DSM 555	5
<i>Clostridium novyi</i>	ATCC19402	45
<i>Clostridium novyi</i>	NT	40
<i>Clostridium perfringens</i> APRT	SM101	5
<i>Clostridium perfringens</i>	13	111
<i>Clostridium perfringens</i>	ATCC 13124	66
<i>Clostridium perfringens</i> S		20
<i>Clostridium perfringens</i>	SM101	65
<i>Clostridium perfringens</i> HPT	13	5
<i>Clostridium perfringens</i> HPT	ATCC 13124	10
<i>Clostridium perfringens</i> HPT	SM101	10
<i>Clostridium perfringens</i> plasmid	plasmid pCP13	5
<i>Clostridium tetani</i>	E88	55
<i>Clostridium tetani</i> HPT	tetani	5
<i>Clostridium thermocellum</i>	ATCC 27405	15
<i>Corynebacterium diphtheriae</i>	diphtheriae	5
<i>Corynebacterium diphtheriae</i>	NCTC 13129	165
<i>Corynebacterium efficiens</i>	YS-314	65
<i>Corynebacterium glutamicum</i>	ATCC 13032	20
<i>Corynebacterium glutamicum</i>	R	69
<i>Corynebacterium glutamicum</i> APRT	ATCC 13032	5
<i>Corynebacterium jeikeium</i>	K411	110
<i>Coxiella burnetii</i>	CbuG Q212	15
<i>Coxiella burnetii</i>	Dugway 5J108-111	25
<i>Coxiella burnetii</i>	MSU Goat Q117	29
<i>Coxiella burnetii</i>	RSA 331	15
<i>Coxiella burnetii</i>	RSA 334	5

<i>Coxiella burnetii</i>	RSA 493	178
<i>Coxiella burnetii</i> HPT	Dugway	5
<i>Coxiella burnetii</i> HPT	burnetti	10
<i>Enterococcus faecalis</i>	faecalis	5
<i>Enterococcus faecalis</i>	MMH594	5
<i>Enterococcus faecalis</i>	V583	145
<i>Enterococcus faecalis</i> APRT	V583	5
<i>Enterococcus faecalis</i> HPT	faecalis	5
<i>Escherichia coli</i>	536	1035
<i>Escherichia coli</i>	1226	5
<i>Escherichia coli</i>	1334	5
<i>Escherichia coli</i>	55989	20
<i>Escherichia coli</i>	042	70
<i>Escherichia coli</i>	17-2	25
<i>Escherichia coli</i>	536 (UPEC)	30
<i>Escherichia coli</i>	B171	85
<i>Escherichia coli</i>	C1845	5
<i>Escherichia coli</i>	CFT 073 (UPEC)	516
<i>Escherichia coli</i>	coli	182
<i>Escherichia coli</i>	coli/shigella	5
<i>Escherichia coli</i>	E. coli plasmid pC15-1a_016	5
<i>Escherichia coli</i>	E/99 3-2 SHV	10
<i>Escherichia coli</i>	E2348/69	285
<i>Escherichia coli</i>	E45035	5
<i>Escherichia coli</i>	EC7372	5
<i>Escherichia coli</i>	EU2657	5
<i>Escherichia coli</i>	EU4855 plasmid	5
<i>Escherichia coli</i>	H11128	25
<i>Escherichia coli</i>	H11129	5
<i>Escherichia coli</i>	K12	38
<i>Escherichia coli</i>	K12 substr. MG1655	25
<i>Escherichia coli</i>	K983802	5
<i>Escherichia coli</i>	KS52	5
<i>Escherichia coli</i>	O157:H7 EDL933	345
<i>Escherichia coli</i>	plasmid	15
<i>Escherichia coli</i>	plasmid p541	5
<i>Escherichia coli</i>	plasmid pEC365	5
<i>Escherichia coli</i>	plasmid pGR2439	5
<i>Escherichia coli</i>	plasmid pMEL2	3
<i>Escherichia coli</i>	plasmid RZA92	5
<i>Escherichia coli</i>	Sakai(EHEC O157:H7)	11
<i>Escherichia coli</i>	SMS-3-5	20
<i>Escherichia coli</i>	Str. 01 (APEC)	50
<i>Escherichia coli</i>	Toho-1	5
<i>Escherichia coli</i>	UTI89 (UPEC)	65
<i>Escherichia coli</i>	YMC02/08/U310	5
<i>Escherichia coli</i>	SMS-3-5	5
<i>Escherichia coli</i> APRT	O157:H7 EDL933	5
<i>Escherichia coli</i> HPT	ATCC 8739	5
<i>Escherichia coli</i> HPT	E24377A	5

<i>Escherichia coli</i> HPT	F11	4
<i>Escherichia coli</i> HPT	HS	5
<i>Escherichia coli</i> plasmid	plasmid pAPEC-O1-ColBM	40
<i>Escherichia coli</i> strain EO 516	EO 516	5
<i>Francisella holartica</i> APRT	OSU18	5
<i>Francisella holartica</i>	FTNF002-00	15
<i>Francisella holartica</i>	holartica	31
<i>Francisella holartica</i>	LVS	35
<i>Francisella holartica</i>	OSU18	25
<i>Francisella holartica</i> HPT	holartica	10
<i>Francisella holartica</i> SNP	FSC022	40
<i>Francisella holartica</i> SNP	FTNF002-00	80
<i>Francisella holartica</i> SNP	HOL 257	20
<i>Francisella holartica</i> SNP	holartica	240
<i>Francisella holartica</i> SNP	LVS	20
<i>Francisella holartica</i> SNP	OSU18	100
<i>Francisella novicida</i>	U112	105
<i>Francisella novicida</i> HPT	U112	5
<i>Francisella novicida</i> SNP	GA99-3548	700
<i>Francisella novicida</i> SNP	novicida	7480
<i>Francisella novicida</i> SNP	U112	620
<i>Francisella tularensis</i>	ATCC 6223	46
<i>Francisella tularensis</i>	francisella	5
<i>Francisella tularensis</i>	fsc033	5
<i>Francisella tularensis</i>	FSC198	15
<i>Francisella tularensis</i>	plasmid pOM1	5
<i>Francisella tularensis</i>	SCHU S4	411
<i>Francisella tularensis</i>	tularensis	52
<i>Francisella tularensis</i>	WY96-3418	55
<i>Francisella tularensis</i> SNP	SCHU	180
<i>Francisella tularensis</i> SNP	tularensis	580
<i>Francisella tularensis</i> SNP	WY96	100
<i>Francisella tularensis</i> SNP	WY96-3418	20
<i>Francisella</i>	Francisella	15
<i>Francisella holartica/novicida</i>	holartica/novicida	5
<i>Francisella holartica/tularensis</i>	holartica/tularensis	25
<i>Francisella novicida/tularensis</i>	novicida/tularensis	30
<i>Francisella tularensis/holartica</i> SNP	tularensis/holartica	20
<i>Haemophilus ducreyi</i>	35000 HP	405
<i>Haemophilus influenzae</i> APRT	86-028NP	5
<i>Haemophilus influenzae</i> APRT	Rd KW20	5
<i>Haemophilus influenzae</i>	12	30
<i>Haemophilus influenzae</i>	1007	89
<i>Haemophilus influenzae</i>	3179B	5
<i>Haemophilus influenzae</i>	86-028NP	336
<i>Haemophilus influenzae</i>	AM30	25
<i>Haemophilus influenzae</i>	C54	5
<i>Haemophilus influenzae</i>	influenzae	5
<i>Haemophilus influenzae</i>	N187	5
<i>Haemophilus influenzae</i>	Pitt EE	275

<i>Haemophilus influenzae</i>	Pitt GG	299
<i>Haemophilus influenzae</i>	Rd	95
<i>Haemophilus influenzae</i>	Rd KW20	375
<i>Haemophilus somnus</i>	2336	205
<i>Haemophilus somnus</i>	129 PT	380
<i>Helicobacter acinonychis</i>	Sheeba	279
<i>Helicobacter hepaticus</i>	ATCC 51449	250
<i>Helicobacter pylori</i> APRT	J99	5
<i>Helicobacter pylori</i>	26695	438
<i>Helicobacter pylori</i>	HPAG1	377
<i>Helicobacter pylori</i>	J99	484
<i>Human</i>	Human	100
<i>Klebsiella pneumonia</i> APRT	MGH 78578	5
<i>Lactobacillus delbrueckii</i> APRT	subsp. bulgaricus ATCC 11842	5
<i>Legionella pneumophila</i>	Philadelphia 1	793
<i>Legionella pneumophila</i> HPT	Corby	3
<i>Legionella pneumophila</i> HPT	Lens	5
<i>Legionella pneumophila</i> HPT	Paris	10
<i>Legionella pneumophila</i> HPT	Philadelphia 1	5
<i>Legionella pneumophila</i>	Corby	296
<i>Legionella pneumophila</i>	Lens	378
<i>Legionella pneumophila</i>	Paris	399
<i>Legionella pneumophila</i>	pneumophila	5
<i>Listeria innocua</i>	Clip 11262	105
<i>Listeria ivanovii</i>	ATCC 19119	5
<i>Listeria monocytogenes</i>	monocytogenes	10
<i>Listeria monocytogenes</i> APRT	EGD-e	5
<i>Listeria monocytogenes</i> HPT	4b 2365	10
<i>Listeria monocytogenes</i> HPT	EGD-e	5
<i>Listeria monocytogenes</i>	4b 2365	260
<i>Listeria monocytogenes</i>	EGD-e sv 1/2A	453
<i>Listeria monocytogenes</i>	F2365	95
<i>Listeria monocytogenes</i> APRT	F2365	5
<i>Listeria monocytogenes</i> SNP	J1-194	1280
<i>Listeria monocytogenes</i> SNP	J2-064	80
<i>Listeria monocytogenes</i>	J2-064	5
<i>Listeria monocytogenes</i> SNP	monocytogenes	5180
<i>Listeria welshimeri</i> APRT	SLCC 5334	5
<i>Listeria welshimeri</i>	SLCC 5334	100
<i>Mycobacterium avium</i> APRT	K-10 ss paratuberculosis	5
<i>Mycobacterium avium</i>	104	263
<i>Mycobacterium avium</i>	K-10 ss paratuberculosis	743
<i>Mycobacterium bovis</i> APRT	BCG str. Pasteur 1173P2	5
<i>Mycobacterium bovis</i>	AF2122/97	15
<i>Mycobacterium bovis</i>	BCG Pasteur 1173P2	15
<i>Mycobacterium gilvums</i>	PYR-GCK	619
<i>Mycobacterium leprae</i> APRT	TN	5
<i>Mycobacterium leprae</i>	TN	379
<i>Mycobacterium marinum</i> APRT	M	5
<i>Mycobacterium smegmatis</i>	MC2155	543

<i>Mycobacterium tuberculosis</i> APRT	CDC 1551	5
<i>Mycobacterium tuberculosis</i>	CDC 1551	120
<i>Mycobacterium tuberculosis</i>	F11	15
<i>Mycobacterium tuberculosis</i>	H37 Ra	5
<i>Mycobacterium tuberculosis</i>	H37 Rv	682
<i>Mycobacterium tuberculosis</i>	tuberculosis/bovis	5
<i>Mycobacterium ulcerans</i>	Agy 99	504
<i>Mycobacterium ulcerans</i> APRT	Agy99	5
<i>Mycobacterium ulcerans</i> plasmid	Agy99 plasmid pMUM001	20
<i>Mycobacterium van baalenii</i>	PYR-1	702
<i>Mycobacterium</i> sp.	JLS	650
<i>Mycobacterium</i> sp.	KMS	120
<i>Mycobacterium</i> sp.	MCS	45
<i>Mycoplasma agalactiae</i>	PG2	45
<i>Mycoplasma capricolum</i>	ATCC 27343	10
<i>Mycoplasma gallisepticum</i>	R	230
<i>Mycoplasma genitalium</i>	G37	50
<i>Mycoplasma hyopneumoniae</i> APRT	7448	4
<i>Mycoplasma hyopneumoniae</i> APRT	J	7
<i>Mycoplasma hyopneumoniae</i>	232	70
<i>Mycoplasma hyopneumoniae</i>	7448	35
<i>Mycoplasma hyopneumoniae</i>	J	30
<i>Mycoplasma mobile</i>	163K	105
<i>Mycoplasma mycoides</i> APRT	PG1	5
<i>Mycoplasma mycoides</i>	PG1	90
<i>Mycoplasma penetrans</i>	HF-2	250
<i>Mycoplasma pneumoniae</i> APRT	M129	5
<i>Mycoplasma pneumoniae</i>	M129	50
<i>Mycoplasma pneumoniae</i>	pneumoniae	5
<i>Mycoplasma pulmonis</i> APRT	UAB CTIP	5
<i>Mycoplasma pulmonis</i>	UABCTIP	74
<i>Mycoplasma synoviae</i>	53	10
<i>Neisseria gonorrhoeae</i>	FA 1090	205
<i>Neisseria meningitidis</i>	FAM18	188
<i>Neisseria meningitidis</i>	MC58	274
<i>Neisseria meningitidis</i>	neisseria	5
<i>Neisseria meningitidis</i>	str. 053442	164
<i>Neisseria meningitidis</i>	Z2491	281
Plasmid pBC16	Plasmid pBC16	5
Plasmid pLS1	Plasmid pLS1	5
<i>Pseudomonas aeruginosa</i> HPT	2192 Paer2_01_70	5
<i>Pseudomonas aeruginosa</i> HPT	PA01	10
<i>Pseudomonas aeruginosa</i> HPT	PA7	5
<i>Pseudomonas aeruginosa</i>	aeruginosa	5
<i>Pseudomonas aeruginosa</i>	PA01	1274
<i>Pseudomonas aeruginosa</i>	PA7	1015
<i>Pseudomonas aeruginosa</i>	UCBPP-PA14	317
<i>Pseudomonas entomophila</i> HPT	L48	5
<i>Pseudomonas entomophila</i>	L48	558
<i>Pseudomonas fluorescens</i> HPT	Pf-5	5

<i>Pseudomonas fluorescens</i> HPT	PfO-1	5
<i>Pseudomonas fluorescens</i>	Pf-5	710
<i>Pseudomonas fluorescens</i>	PfO-1	590
<i>Pseudomonas mendocina</i> HPT	ymp	5
<i>Pseudomonas mendocina</i>	ymp	645
<i>Pseudomonas putida</i> APRT	KT 2440	5
<i>Pseudomonas putida</i> HPT	GB-1	5
<i>Pseudomonas putida</i> HPT	KT 2440	5
<i>Pseudomonas putida</i>	F1	430
<i>Pseudomonas putida</i>	GB-1	607
<i>Pseudomonas putida</i>	KT 2440	706
<i>Pseudomonas putida</i>	W619	560
<i>Pseudomonas stutzeri</i>	A1501	480
<i>Pseudomonas stutzeri</i> HPT	A1501	5
<i>Pseudomonas syringae</i> APRT	pv. phaseolicola 1448A	5
<i>Pseudomonas syringae</i>	1448A	1042
<i>Pseudomonas syringae</i>	B728a	1021
<i>Pseudomonas syringae</i>	DC3000	1214
<i>Pseudomonas syringae</i> HPT	pv. phaseolicola 1448A	7
<i>Pseudomonas syringae</i> HPT	pv. syringae B728a	5
<i>Pseudomonas syringae</i> HPT	pv. tomato str. DC3000	5
<i>Pseudomonas syringae</i> plasmid	1448A large plasmid	50
<i>Pseudomonas syringae</i> plasmid	plasmid pDC3000A	20
<i>Ricinus communis</i>	communis	20
<i>Rickettsia prowazekii</i>	Madrid E	55
<i>Rickettsia prowazekii</i>	prowazekii	5
<i>Rickettsia rickettsii</i>	Iowa	70
<i>Rickettsia rickettsii</i> SNP	rickettsiae	60
<i>Rickettsia rickettsii</i>	rickettsii/africae/sibirica	5
<i>Rickettsia typhi</i>	Wilmington	55
<i>Salmonella enterica</i> APRT	Typhi str. CT18	5
<i>Salmonella enterica</i>	ATCC 9150 sv paratyphi A	168
<i>Salmonella enterica</i>	CT18	332
<i>Salmonella enterica</i>	enterica	5
<i>Salmonella enterica</i>	LT2	520
<i>Salmonella enterica</i>	RSK 2980 ss arizona sv 62	544
<i>Salmonella enterica</i>	SC-B67 sv Choleraesuis	201
<i>Salmonella enterica</i>	SPB7 sv Paratyphi B	207
<i>Salmonella enterica</i>	sv typhimurium	239
<i>Salmonella enterica</i>	Ty2	10
<i>Salmonella enterica</i> plasmid	pSN254	125
<i>Salmonella enterica</i> plasmid	SC-B67 plasmid pSCV50	10
<i>Salmonella typhimurium</i>	LT2	253
<i>Salmonella typhimurium</i> plasmid	LT2 plasmid pSLT	5
<i>Shigella dysenteriae</i>	plasmid pmK105	5
<i>Shigella boydii</i>	227	43
<i>Shigella boydii</i>	0-1392	20
<i>Shigella boydii</i>	CDC 3083-94	93
<i>Shigella boydii</i>	Sb227	300
<i>Shigella boydii</i> HPT	boydii	5

<i>Shigella boydii</i> plasmid	plasmid pSB4_227	15
<i>Shigella dysenteriae</i> APRT	Sd197	5
<i>Shigella dysenteriae</i>	197	107
<i>Shigella dysenteriae</i>	Sd197	130
<i>Shigella dysenteriae</i> plasmid	plasmid pSD1_197	171
<i>Shigella flexneri</i>	301	866
<i>Shigella flexneri</i>	8401	60
<i>Shigella flexneri</i>	2457T	80
<i>Shigella flexneri</i>	flexneri	45
<i>Shigella flexneri</i>	M90T	248
<i>Shigella flexneri</i>	multiple species	5
<i>shigella flexneri</i> HPT	flexneri	5
<i>Shigella flexneri</i> plasmid	M90T plasmid pWR501	15
<i>Shigella flexneri</i> plasmid	plasmid pPCP301	35
<i>Shigella sonnei</i>	Ss046	66
<i>Shigella sonnei</i> plasmid	str. 046 plasmid pSS_046	15
<i>Staphylococcus aureus</i> APRT	N315	5
<i>Staphylococcus aureus</i> HPT	aureus	5
<i>Staphylococcus aureus</i>	aureus	45
<i>Staphylococcus aureus</i>	COL	140
<i>Staphylococcus aureus</i>	JH1	15
<i>Staphylococcus aureus</i>	JH9	15
<i>Staphylococcus aureus</i>	MRSA 252	255
<i>Staphylococcus aureus</i>	MSSA 476	2
<i>Staphylococcus aureus</i>	Mu3	10
<i>Staphylococcus aureus</i>	Mu50	140
<i>Staphylococcus aureus</i>	MW2	350
<i>Staphylococcus aureus</i>	N315	20
<i>Staphylococcus aureus</i>	NCTC 8325	29
<i>Staphylococcus aureus</i>	Newman	15
<i>Staphylococcus aureus</i>	RF122	203
<i>Staphylococcus aureus</i>	USA 300_TCH 1516	10
<i>Staphylococcus aureus</i>	USA 3000	27
<i>Staphylococcus epidermidis</i> APRT	RP62A	5
<i>Staphylococcus epidermidis</i>	ATCC 12228	62
<i>Staphylococcus epidermidis</i>	RP62A	60
<i>Staphylococcus epidermidis</i> HPT	epideridis	5
<i>Staphylococcus haemolyticus</i>	JCSC 1435	80
<i>Staphylococcus haemolyticus</i> HPT	haemolyticus	5
<i>Staphylococcus saprophyticus</i> HPT	saprophyticus	5
<i>Staphylococcus saprophyticus</i>	ATCC 15305	95
<i>Streptococcus agalactiae</i> APRT	A909	5
<i>Streptococcus agalactiae</i>	2603 V/R	145
<i>Streptococcus agalactiae</i>	A909	200
<i>Streptococcus agalactiae</i>	agalactiae	5
<i>Streptococcus agalactiae</i>	FM027022	5
<i>Streptococcus agalactiae</i>	NEM316	75
<i>Streptococcus agalactiae</i> HPT	agalactiae	5
<i>Streptococcus agalactiae</i> HPT	CJB111	10
<i>Streptococcus gordonii</i>	Challis	150

<i>Streptococcus mutans</i>	UA 159	135
<i>Streptococcus pneumoniae</i> APRT	Hungary 19A-6	5
<i>Streptococcus pneumoniae</i> APRT	R6	5
<i>Streptococcus pneumoniae</i> HPT	Hungary 19A-6	6
<i>Streptococcus pneumoniae</i> HPT	pneumoniae	5
<i>Streptococcus pneumoniae</i> HPT	TIGR4	2
<i>Streptococcus pneumoniae</i>	CGSP14	87
<i>Streptococcus pneumoniae</i>	D39	154
<i>Streptococcus pneumoniae</i>	Hungary 19A-6	130
<i>Streptococcus pneumoniae</i>	pneumoniae	5
<i>Streptococcus pneumoniae</i>	R6	5
<i>Streptococcus pneumoniae</i>	TIGR4	185
<i>Streptococcus pyogenes</i> APRT	M1 GAS	5
<i>Streptococcus pyogenes</i>	Manfredo st M5	50
<i>Streptococcus pyogenes</i>	MGAS 10270 st M2	95
<i>Streptococcus pyogenes</i>	MGAS 10394 st M6	95
<i>Streptococcus pyogenes</i>	MGAS 10750 st M4	83
<i>Streptococcus pyogenes</i>	MGAS 2096 st M12	57
<i>Streptococcus pyogenes</i>	MGAS 315 st M3	85
<i>Streptococcus pyogenes</i>	MGAS 5005 st M1	35
<i>Streptococcus pyogenes</i>	MGAS 6180 st M28	80
<i>Streptococcus pyogenes</i>	MGAS 8232 st M18	65
<i>Streptococcus pyogenes</i>	MGAS 9429 st M12	10
<i>Streptococcus pyogenes</i>	pyogenes	5
<i>Streptococcus pyogenes</i>	SF370	150
<i>Streptococcus pyogenes</i>	SSI-1 st M3	36
<i>Streptococcus pyogenes</i> HPT	MGAS 10394	5
<i>Streptococcus pyogenes</i> HPT	MGAS 10750	5
<i>Streptococcus pyogenes</i> HPT	MGAS 8232	5
<i>Streptococcus pyogenes</i> HPT	pyogenes	5
<i>Streptococcus sanguinis</i>	SK36	232
<i>Streptococcus sanguinis</i> HPT	sanguinis	5
<i>Streptococcus suis</i>	05ZYH33	138
<i>Streptococcus suis</i>	98 HAH33	65
<i>Streptococcus thermophilus</i> HPT	LMG 18311	4
<i>Streptococcus thermophilus</i>	CNRZ1066	117
<i>Streptococcus thermophilus</i>	LMG-9	150
<i>Streptococcus thermophilus</i>	LMG 18311	135
<i>Streptococcus thermophilus</i> HPT	thermophilus	5
<i>Treponema pallidum</i>	Nichols	5
<i>Treponema pallidum</i>	pallidum	5
<i>Treponema pallidum</i>	SS14	30
<i>Ureaplasma parvum</i> APRT	ATCC 27815	5
<i>Vibrio cholerae</i> APRT	O395	5
<i>Vibrio cholerae</i> HPT	623-39	5
<i>Vibrio cholerae</i> HPT	RC385	5
<i>Vibrio cholerae</i>	1587	5
<i>Vibrio cholerae</i>	623-39	10
<i>Vibrio cholerae</i>	all other <i>Vibrio cholerae</i>	60
<i>Vibrio cholerae</i>	cholerae	5

<i>Vibrio cholerae</i>	MAK 757	5
<i>Vibrio cholerae</i>	MZO-2	5
<i>Vibrio cholerae</i>	MZO-3	5
<i>Vibrio cholerae</i>	N16961	1144
<i>Vibrio cholerae</i>	NCTC 8457	5
<i>vibrio cholerae</i>	O395	145
<i>Vibrio cholerae</i>	plasmid pTLC -1	5
<i>Vibrio cholerae</i>	plasmid pTLC -2	5
<i>Vibrio cholerae</i>	plasmid pTLC -3	5
<i>Vibrio cholerae</i>	plasmid pTLC -4	5
<i>Vibrio cholerae</i>	plasmid pTLC -5	5
<i>Vibrio cholerae</i>	RC385	5
<i>Vibrio cholerae</i>	V51	10
<i>Vibrio cholerae</i> HPT	cholerae	5
<i>Vibrio cholerae</i> HPT	V51	5
<i>Vibrio fischeri</i>	ES114	554
<i>Vibrio parahaemolyticus</i>	AQ3810	5
<i>Vibrio parahaemolyticus</i>	parahaemolyticus	5
<i>Vibrio parahaemolyticus</i>	RIMD 2210633	830
<i>Vibrio vulnificus</i>	CMCP6	764
<i>Vibrio vulnificus</i>	<i>Vibrio vulnificus</i>	5
<i>Vibrio vulnificus</i>	YJ016	443
<i>Xanthomonas axonopodis</i> APRT	pv. citri str. 306	5
<i>Yersinia enterocolitica</i>	8081	560
<i>Yersinia enterocolitica</i>	84-50	5
<i>Yersinia enterocolitica</i>	A127	177
<i>Yersinia enterocolitica</i>	W1024	10
<i>Yersinia enterocolitica</i> APRT	8081	5
<i>Yersinia enterocolitica</i> HPT	8081	10
<i>Yersinia enterocolitica</i> plasmid	8081 plasmid pYVe8081	94
<i>Yersinia pestis</i>	91001 bv <i>Microtus</i>	20
<i>Yersinia pestis</i>	Angola	38
<i>Yersinia pestis</i>	Antiqua	50
<i>Yersinia pestis</i>	bv <i>Microtus</i> str. 91001	15
<i>Yersinia pestis</i>	CO92	614
<i>Yersinia pestis</i>	KIM	65
<i>Yersinia pestis</i>	Nepal 516	20
<i>Yersinia pestis</i>	Pestoides F	15
<i>Yersinia pestis</i>	Y. pestis	5
<i>Yersinia pestis</i> APRT	Angola	5
<i>Yersinia pestis</i> APRT	CO92	5
<i>Yersinia pestis</i> APRT	KIM	5
<i>Yersinia pestis</i> HPT	CO92	10
<i>Yersinia pestis</i> plasmid	pIP1202	90
<i>Yersinia pestis</i> plasmid	91001 bv <i>Microtus</i> plasmid pCD1	10
<i>Yersinia pestis</i> plasmid	Angola plasmid pCD	5
<i>Yersinia pestis</i> plasmid	Pestoides F plasmid pCD	13
<i>Yersinia pseudotuberculosis</i>	IP 31758	115
<i>Yersinia pseudotuberculosis</i>	IP 32953	68
<i>Yersinia pseudotuberculosis</i>	pseudotuberculosis	5

<i>Yersinia pseudotuberculosis</i>	YP111	56
<i>Yersinia pseudotuberculosis</i> HPT	PB1/+	10
<i>Yersinia pseudotuberculosis</i> plasmid	IP32953 plasmid YV	12
<i>Yersinia pseudotuberculosis</i> plasmid	plasmid pYps IP31758.1	195
<i>Yersinia pseudotuberculosis</i> plasmid	plasmid pYps IP31758.2	45
<i>Yersinia pestis/pseudotuberculosis</i>	pestis/pseudotuberculosis	10
<i>Yersinia pestis/pseudotuberculosis</i> SNP	IP 31758	20
<i>Yersinia pestis/pseudotuberculosis</i> SNP	pestis/pseudotuberculosis	520

This page intentionally left blank.

Annex B Species and strains used in testing of the completed array design.

Species	Strain / isolate
<i>Acinetobacter baumannii</i>	ATCC 17978
<i>Bacillus anthracis</i>	RP42 (94188c)
<i>Bacillus anthracis</i>	RP42 -A (94188c)
<i>Bacillus anthracis</i>	NH (DB-2)
<i>Bacillus anthracis</i>	Vollum (DB-3)
<i>Bacillus anthracis</i>	Ames PLG6 (DB-5)
<i>Bacillus anthracis</i>	ACB
<i>Bacillus anthracis</i>	94188c (DB-4)
<i>Bacillus cereus</i>	ATCC 11778
<i>Bacillus cereus</i>	ATCC 10987 (CR)
<i>Bartonella henselae</i>	ATCC 49882
<i>Bordetella pertussis</i>	ATCC BAA-589
<i>Burkholderia pseudomallei</i>	Env.81"7" (DB-9)
<i>Burkholderia pseudomallei</i>	Env.FB20"5" (DB-10)
<i>Burkholderia mallei</i>	ATCC 1053"8" (DB-7)
<i>Burkholderia mallei</i>	ATCC 23344"10" (DB-8)
<i>Campylobacter jejuni</i>	ATCC 700819
<i>Clostridium perfringens</i>	ATCC 13124
<i>Escherichia coli</i>	0517:H7 EDL933
<i>Escherichia coli</i>	ATCC 25922
<i>Escherichia coli</i>	JM109
<i>Escherichia coli</i>	JM109 tube 14
<i>Escherichia faecalis</i>	ATCC 29212
<i>Francisella holarctica</i>	DB-15 Swed 4Q
<i>Francisella holarctica</i>	Swed 6Q (DB-16)
<i>Francisella holarctica</i>	Swed 3 (DB-14)
<i>Francisella holarctica</i>	Swed 9 (DB-19)
<i>Francisella holarctica</i>	Swed 10 (DB-20)
<i>Francisella holarctica</i>	FT-65-4 (DB-21)
<i>Francisella holarctica</i>	FT-67-4 (DB-22)
<i>Francisella mediasiatica</i>	Swed 8 6 (DB-18)
<i>Francisella tularensis</i>	A1 Swed 1 (DB-11)
<i>Francisella tularensis</i>	A1 Swed 1 (DB-11)
<i>Francisella tularensis</i>	A1 Swed 2Q (DB-13)
<i>Francisella tularensis</i>	A II Swed 7Q (DB-17)
<i>Francisella tularensis</i>	Swed 2 (1D1) (DB-12)
<i>Haemophilus influenzae</i>	ATCC 51907

<i>Listeria monocytogenes</i>	ATCC 15313
<i>Listeria monocytogenes</i>	NTCC 7937
<i>Listeria monocytogenes</i>	ATCC 15313
<i>Mycobacterium BCG</i>	ATCC 19015
<i>Mycoplasma pneumoniae FH</i>	ATCC 15531
<i>Pseudomonas aeruginosa</i>	ATCC 27853
<i>Salmonella typhimurium</i>	71-471
<i>Staphylococcus aureus</i>	Z1
<i>Staphylococcus dysenteriae</i>	ATCC 11835
<i>Staphylococcus pyogenes</i>	ATCC 19615
<i>Vibrio vulnificus</i>	Z28
<i>Yersinia aldovae</i>	ATCC 35237
<i>Yersinia bercovieri</i>	CCRI 14920
<i>Yersinia enterocolytica</i>	CCUG 33553
<i>Yersinia enterocolytica</i>	#14 field strain
<i>Yersinia enterocolytica</i>	CCUG 31436
<i>Yersinia enterocolytica</i>	#7 field strain
<i>Yersinia enterocolytica</i>	ATCC 23715
<i>Yersinia enterocolitica</i>	YE-D3
<i>Yersinia frederiksenii</i>	CCRI 14915
<i>Yersinia intermedia</i>	ATCC 33648
<i>Yersinia kristensenii</i>	ATCC 33638
<i>Yersinia mollaretii</i>	ATCC 43969 (DB-30)
<i>Yersinia pestis</i>	PX14-3
<i>Yersinia pestis</i>	CO92 (DB-31)
<i>Yersinia pestis</i>	C12
<i>Yersinia pestis</i>	GB
<i>Yersinia pestis</i>	PP65-BC YC-1D (BF)
<i>Yersinia pestis</i>	ATCC 19428
<i>Yersinia pseudotuberculosis</i>	ATCC 29833
<i>Yersinia pseudotuberculosis</i>	ATCC 6902
<i>Yersinia pseudotuberculosis</i>	ATCC 13979 (CR)
<i>Yersinia rohdei</i>	CCRI 14919 (DB-36)
<i>Yersinia ruckeria</i>	ATCC 29473 (DB-37)

DOCUMENT CONTROL DATA		
(Security classification of title, body of abstract and indexing annotation must be entered when the overall document is classified)		
1. ORIGINATOR (The name and address of the organization preparing the document. Organizations for whom the document was prepared, e.g. Centre sponsoring a contractor's report, or tasking agency, are entered in section 8.) Defence R&D Canada – Suffield P.O. Box 4000, Station Main Medicine Hat, Alberta T1A 8K6	2. SECURITY CLASSIFICATION (Overall security classification of the document including special warning terms if applicable.) UNCLASSIFIED (NON-CONTROLLED GOODS) DMC A REVIEWED: GCEC JUNE 2010	
3. TITLE (The complete document title as indicated on the title page. Its classification should be indicated by the appropriate abbreviation (S, C or U) in parentheses after the title.) Microarray systems for microbial detection and identification:		
4. AUTHORS (last name, followed by initials – ranks, titles, etc. not to be used) Ford, B., Bader, D.		
5. DATE OF PUBLICATION (Month and year of publication of document.) October 2010	6a. NO. OF PAGES (Total containing information, including Annexes, Appendices, etc.) 48	6b. NO. OF REFS (Total cited in document.) 23
7. DESCRIPTIVE NOTES (The category of the document, e.g. technical report, technical note or memorandum. If appropriate, enter the type of report, e.g. interim, progress, summary, annual or final. Give the inclusive dates when a specific reporting period is covered.) Technical Report		
8. SPONSORING ACTIVITY (The name of the department project office or laboratory sponsoring the research and development – include address.) Defence R&D Canada – Suffield P.O. Box 4000, Station Main Medicine Hat, Alberta T1A 8K6		
9a. PROJECT OR GRANT NO. (If appropriate, the applicable research and development project or grant number under which the document was written. Please specify whether project or grant.)	9b. CONTRACT NO. (If appropriate, the applicable number under which the document was written.)	
10a. ORIGINATOR'S DOCUMENT NUMBER (The official document number by which the document is identified by the originating activity. This number must be unique to this document.) DRDC Suffield TR 2010-203	10b. OTHER DOCUMENT NO(s). (Any other numbers which may be assigned this document either by the originator or by the sponsor.)	
11. DOCUMENT AVAILABILITY (Any limitations on further dissemination of the document, other than those imposed by security classification.) Unlimited		
12. DOCUMENT ANNOUNCEMENT (Any limitation to the bibliographic announcement of this document. This will normally correspond to the Document Availability (11). However, where further distribution (beyond the audience specified in (11) is possible, a wider announcement audience may be selected.) Unlimited		

13. **ABSTRACT** (A brief and factual summary of the document. It may also appear elsewhere in the body of the document itself. It is highly desirable that the abstract of classified documents be unclassified. Each paragraph of the abstract shall begin with an indication of the security classification of the information in the paragraph (unless the document itself is unclassified) represented as (S), (C), (R), or (U). It is not necessary to include here abstracts in both official languages unless the text is bilingual.)

The relatively recent availability of complete or near-complete sequences of microbial DNA makes it possible to find and exploit unique genetic markers for most microbes. Using microbial genome sequences from public databases, a high-density microarray system has been developed which should enable the identification of hundreds of individual species or strains of pathogenic microorganisms on a single assay platform. This report summarizes the design, development, and testing of this microarray design. The system is currently capable of discriminating multiple human pathogens, Category A biothreats, and some agricultural pathogens, other using supervised analysis methods. Ongoing development will include tools for automation of analysis, and extension of the testing panel of microbes.

14. **KEYWORDS, DESCRIPTORS or IDENTIFIERS** (Technically meaningful terms or short phrases that characterize a document and could be helpful in cataloguing the document. They should be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code name, geographic location may also be included. If possible keywords should be selected from a published thesaurus, e.g. Thesaurus of Engineering and Scientific Terms (TEST) and that thesaurus identified. If it is not possible to select indexing terms which are Unclassified, the classification of each should be indicated as with the title.)

microarray, genomic fingerprinting, detection/identification, microbe, category A

Defence R&D Canada

Canada's Leader in Defence
and National Security
Science and Technology

R & D pour la défense Canada

Chef de file au Canada en matière
de science et de technologie pour
la défense et la sécurité nationale

